The Efficacy of Sodium Butyrate and Probiotics in Patients With Irritable Bowel Syndrome
Key facts
- Who runs it
- Nordic Biotic Sp. z o.o.
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 120 people enrolled
- Started
- 15 Apr 2021
- Ended
- 31 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Probiotics and microcapsulated sodium butyrate
- Maltodextrin
- Record updated
- 28 February 2024
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Males and females aged from 18 to 70 years, inclusive
- Good physical and mental condition assessed based on the patient's history and physical examination
- Laboratory test results (complete blood count, blood chemistry panel) within normal limits or considered not to be clinically significant by the Investigator; negative SARS-CoV-2 antibody test
- A voluntarily provided written informed consent
- Diagnosis of IBS based on the Rome IV criteria, e.g. recurrent abdominal pain at least one day a week for the last three months, associated with two or more of the following symptoms (these should be present for the last three months, with the onset of symptoms six months before diagnosis):; related to defecation; associated with a change in stool frequency and/or; associated with a change in stool form (appearance); Patients with any of the following forms of IBS will be included:; IBS-D - more than 25% of BSF type 6 and 7 stools, and less than 25% of type 1 and 2 stools; IBS-C - more than 25% of BSF type 1 and 2 stools, with less than 25% of type 6 and 7 stools; IBS-M - more than 25% of BSF type 6 and 7 stools and also more than 25% of type 1 and 2 stools; at least moderate symptom severity defined as an IBS-SSS score of >175 (5 items, maximum score 500)
- The following medications are allowed during this study, provided they have been used at a stable dose and for at least 1 month prior to the study:; contraceptive pills or intramuscular contraceptives,; hormone replacement therapy (estrogen/progesterone),; L-thyroxine,; antidepressants at low doses (up to 25 mg of amitriptyline, nortriptyline, or selective serotonin reuptake inhibitor per day); antihypertensives at low doses (diuretics, angiotensin converting enzyme inhibitors angiotensin receptor antagonists)
Who cannot take part
- The use of antithrombotic drugs
- A surgical procedure scheduled during the course of the clinical study
- Current probiotic use and refusal to undergo a 3-month washout period
- Antibiotic therapy during the 3 months preceding the study
- Being included in another clinical study during the previous 3 months
- Cardiovascular disorders: uncontrolled hypertension (blood pressure >170/100 mmHg), cerebrovascular disease
- Respiratory disorders (asthma, chronic obstructive pulmonary disease [COPD])
- Gastrointestinal conditions other than IBS, including clinical or endoscopic diagnosis of gastroenteritis
- Severe neurological conditions, with psychosis
- Malignancy
- Hypersensitivity to soy
- History of alcohol or substance
- Hepatic impairment (including status post cholecystectomy), renal impairment, and unexplained blood biochemistry abnormalities: serum creatinine levels over twice the upper limit of normal, AST or ALT levels over twice the upper limit of normal
- Endocrine disorders, including diabetes mellitus (fasting blood glucose >11 mmol/L) and elevated TSH levels
- Unclassified IBS
- Pregnancy or breastfeeding
- Lactose intolerance
- The use of gastrointestinal motility stimulants or dietary fiber supplements during the 2 weeks preceding the clinical study
- Antibiotic use during the study
- Inability to strictly adhere to the Investigators' instructions regarding study procedures and protocol requirements.abuse
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
According to current IBS management guidelines, probiotic administration reduces IBS-associated symptoms and improves the quality of life. The purpose of this study is to assess the effects of the combined formulation comprising microencapsulated sodium butyrate and a probiotic mixture of two Lactobacillus strains (L. rhamnosus and L. acidophilus) and three Bifidobacterium strains (B. longum, B. bifidum, and B. lactis) on the incidence and severity of clinical symptoms in patients diagnosed with irritable bowel syndrome (IBS) based on the Rome IV criteria.
Read full original descriptionShow less
Microencapsulated sodium butyrate is a short-chain fatty acid (SCFA) with biological effects on the gastrointestinal mucosa; it constitutes a key source of energy for enterocytes. Butyrate was shown to have a trophic effect on the colon epithelium and to help restore the disrupted structural and functional integrity of the gastrointestinal tract. These unique properties of sodium butyrate result in its beneficial effects on the abdominal symptoms (such as diarrhea, constipation, abdominal pain) in patients with IBS. This study will assess the effects of the mixture of sodium butyrate and multi-strain probiotic on the rate and severity of clinical symptoms in IBS patients, by taking into account their nutritional status and body composition.
The 2 groups in the trial
- The mixture of probiotics and microcapsulated sodium butyrateExisting treatment, for comparison
One billion of the following strains: Bifidobacterium lactis FloraActive 32269, Bifidobacterium longum FloraActive 32946, Bifidobacterium bifidum FloraActive 32043, Lactobacillus rhamnosus FloraActive 19070-2, Lactobacillus acidophilus FloraActive 32418 and 150 mg microcapsulated sodium butyrate, and 64 mg fructooligosaccharides
Treatment: Probiotics and microcapsulated sodium butyrate
- PlaceboPlacebo, for comparison
Maltodextrin
Treatment: Maltodextrin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Assessment of the Efficacy of Microencapsulated Sodium Butyrate and a Probiotic Mixture in Patients With Irritable Bowel Syndrome - a Randomized Double-blind Placebo-controlled Study
- Publications
- Sodium butyrate prevents cytokine-induced β-cell dysfunction through restoration of stromal interaction molecule 1 expression and activation of store-operated calcium entry.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2024
- Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of a Randomized Double-Blind Placebo-Controlled Trial.Journal of clinical medicine, 2022
- Record updated
- 28 February 2024